DG
Debolina Ganguly
Harvard Medical School, Dana-Farber Cancer Institute, University of Texas Southwestern Medical Center
0000-0002-7184-0053
Employment
-
Harvard Medical School Post doctoral Research Fellow2023 - Present
-
Dana-Farber Cancer Institute Post doctoral Research Fellow2023 - Present
Education
-
University of Texas Southwestern Medical Center PhD2017 - 2023
Projects & Funding
Projects & funding information is unavailable.
Publications (22)
- Data from Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma Save
- Supplementary Figure S5 from Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma Save
- Supplementary Figure S5 from Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma Save
- Supplementary Figure S4 from Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma Save
- Supplementary Figure S4 from Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma Save
- Supplementary Figure S3 from Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma Save
- Supplementary Figure S3 from Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma Save
- Supplementary Figure S2 from Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma Save
- Supplementary Figure S2 from Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma Save
- Supplementary Figure S1 from Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma Save